Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 2, 2004The Prostate

Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PBPatrick BurchMayo Clinic in ArizonaGCGary A. CroghanFox Chase Cancer CenterDGDennis A. GastineauMayo Clinic

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Burch et al. (2004) studied this question.

synapsesocial.com/papers/6a0cbedee8bb85e2598415e8https://doi.org/10.1002/pros.20040
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Trials in Relapsed Prostate Cancer: Defining the Target1996 · 121 citations
  2. 2Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study1999 · 894 citations
  3. 3GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial1999 · 70 citations
  4. 4Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.1997 · 211 citations
  5. 5Dendritic Cell-Based Immunotherapy of Prostate Cancer1998 · 109 citations